Latest news
Cardiovascular study on Medox and cholesterol and CETP
A human, randomized, double blind, placebo controlled study done was at one of Chinas 10 leading research universities (China has 1.200 universities). The study had been worked on for 3 years and showed that Medox modulates the cholesterol (Increase HDL and lower LDL) significantly (close to 30%).
Interesting enough, the cholesterol modulation was achieved by lowering the CETP enzyme. This study was published in “The American journal of Clinical Nutrition” USA, in the summer 2009.
In their study, the medical researchers conclude about Medox:
“The observed changes in HDL and LDL are noteworthy because the anthocyanin extract (Medox) is derived from berry food stuff. Changes in these risk factors are clinical relevant. To put this into perspective, it has been reported that cardiovascular disease event rate is reduced by nearly 1% for each 1% reduction of LDL and by more than 1% for each 1% increase in HDL. Therefore, the 13,6 decrease in LDL and 13,7% increase in HDL would result in a nearly 27,3% reduction in coronary heart disease risk, which is meaningful and great promising.”
The CETP protein has been the target for statin replacement by some of the big pharma companies for some years now. Pfizer spent about one billion before they in phase III abandoned their CETP lowering medicine, Torcetrapid. This medicine carried a side effect increasing blood pressure, and hence could not be used. The interesting thing is that researchers at the Ullevål University Hospital in Oslo, has shown that Medox in addition to a lot of other effects do lower blood pressure.